ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.

Frontiers in oncology（2023）

引用 0|浏览35

暂无评分

摘要

Personalized, longitudinal ctDNA monitoring can detect recurrence early in patients with unresectable NSCLC patients undergoing curative radiation and potentially risk-stratify patients who might benefit most from treatment intensification.

查看译文

关键词

circulating tumor DNA (ctDNA),tumor-informed,molecular residual disease (MRD),non-small cell lung cancer (NSCLC),definitive radiation,prognostic biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要